Tianshui Zhongxing Bio-technology Co.,Ltd.
SZSE:002772.SZ
8.17 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,935.227 | 1,931.078 | 1,970.274 | 1,556.147 | 1,483.178 | 1,155.832 | 926.432 | 739.793 | 585.018 | 479.52 | 383.497 | 263.941 | 190.402 | 131.315 |
| Cost of Revenue
| 1,531.917 | 1,494.218 | 1,468.795 | 1,268.172 | 1,073.864 | 879.53 | 668.462 | 505.869 | 356.115 | 282.06 | 237.804 | 172.707 | 99.702 | 55.425 |
| Gross Profit
| 403.311 | 436.86 | 501.479 | 287.975 | 409.315 | 276.303 | 257.97 | 233.924 | 228.904 | 197.46 | 145.693 | 91.234 | 90.7 | 75.89 |
| Gross Profit Ratio
| 0.208 | 0.226 | 0.255 | 0.185 | 0.276 | 0.239 | 0.278 | 0.316 | 0.391 | 0.412 | 0.38 | 0.346 | 0.476 | 0.578 |
| Reseach & Development Expenses
| 14.22 | 12.922 | 10.414 | 7.165 | 7.207 | 3.442 | 3.194 | 1.312 | 1.368 | 2.169 | 3.235 | 1.955 | 1.43 | 0 |
| General & Administrative Expenses
| 27.857 | 25.522 | 26.867 | 43.754 | 25.956 | 16.723 | 17.544 | 18.581 | 14.574 | 17.749 | 2.665 | 1.489 | 5.319 | 22.356 |
| Selling & Marketing Expenses
| 152.308 | 150.005 | 159.971 | 131.922 | 120.891 | 100.781 | 118.166 | 93.557 | 51.517 | 43.328 | 33.746 | 24.773 | 16.73 | 7.5 |
| SG&A
| 180.165 | 241.023 | 186.838 | 175.676 | 146.847 | 117.504 | 135.71 | 112.138 | 66.091 | 61.077 | 36.411 | 26.263 | 22.049 | 29.855 |
| Other Expenses
| 82.427 | 23.993 | 33.713 | 4.54 | 31.038 | 24.837 | -1.186 | 4.08 | 8.26 | 10.59 | 6.644 | 3.685 | 3.558 | 2.64 |
| Operating Expenses
| 278.099 | 277.939 | 230.964 | 187.381 | 185.092 | 145.784 | 168.116 | 134.24 | 93.959 | 84.638 | 55.01 | 38.643 | 28.664 | 29.855 |
| Operating Income
| 125.211 | 158.921 | 307.608 | 121.635 | 271.615 | 166.46 | 113.932 | 138.698 | 153.535 | 104.422 | 84.163 | 51.016 | 60.43 | 40.936 |
| Operating Income Ratio
| 0.065 | 0.082 | 0.156 | 0.078 | 0.183 | 0.144 | 0.123 | 0.187 | 0.262 | 0.218 | 0.219 | 0.193 | 0.317 | 0.312 |
| Total Other Income Expenses Net
| 1.387 | 3.897 | -148.71 | -67.319 | -82.119 | -97.439 | -1.186 | 4.08 | 8.259 | 10.585 | 6.644 | 3.685 | 3.558 | 2.64 |
| Income Before Tax
| 126.598 | 162.818 | 158.898 | 54.316 | 189.496 | 69.022 | 112.746 | 142.778 | 161.339 | 115.007 | 90.807 | 54.701 | 63.988 | 43.576 |
| Income Before Tax Ratio
| 0.065 | 0.084 | 0.081 | 0.035 | 0.128 | 0.06 | 0.122 | 0.193 | 0.276 | 0.24 | 0.237 | 0.207 | 0.336 | 0.332 |
| Income Tax Expense
| 0 | 3.263 | 0.004 | 66.667 | 82.656 | 98.056 | 44.649 | 47.678 | 34.642 | 18.406 | 9.4 | 5.884 | 4.54 | -5.098 |
| Net Income
| 128.029 | 159.581 | 158.352 | -12.351 | 106.84 | -29.035 | 111.939 | 142.273 | 158.51 | 114.381 | 90.881 | 54.75 | 63.992 | 43.576 |
| Net Income Ratio
| 0.066 | 0.083 | 0.08 | -0.008 | 0.072 | -0.025 | 0.121 | 0.192 | 0.271 | 0.239 | 0.237 | 0.207 | 0.336 | 0.332 |
| EPS
| 0.33 | 0.41 | 0.4 | -0.032 | 0.32 | -0.081 | 0.31 | 0.39 | 0.49 | 0.43 | 0.39 | 0.24 | 0.29 | 1.36 |
| EPS Diluted
| 0.33 | 0.41 | 0.4 | -0.032 | 0.32 | -0.081 | 0.3 | 0.38 | 0.47 | 0.41 | 0.39 | 0.24 | 0.29 | 1.36 |
| EBITDA
| 481.572 | 515.871 | 524.79 | 389.707 | 513.925 | 334.758 | 282.057 | 238.976 | 234.129 | 185.279 | 142.877 | 92.619 | 86.501 | 46.034 |
| EBITDA Ratio
| 0.249 | 0.267 | 0.266 | 0.25 | 0.347 | 0.29 | 0.304 | 0.323 | 0.4 | 0.386 | 0.373 | 0.351 | 0.454 | 0.351 |